Real-world Evidence Study on Brentuximab Vedotin Retreatment Outcomes of Cutaneous T-cell Lymphoma Patients (Brentuximab-5020)

24/05/2023
30/10/2025
EU PAS number:
EUPAS104804
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Brentuximab-5020-clinical-study-protocol-redact.pdf

English (1.95 MB - PDF) View document
Updated protocol

Brentuximab-5020-clinical-study-protocol amendment-redact.pdf

First published: 30/10/2025
English (2.14 MB - PDF) View document
Study results
Study report
Study report

Brentuximab-5020-clinical-study-report-redact.pdf

English (817.93 KB - PDF) View document
Other information